

**STRIDES PHARMA ASIA PTE. LTD**  
**BALANCE SHEET AS AT 31 MARCH 2023**

Amount in USD

	Particulars	Note No.	31-Mar-23	31-Mar-22
<b>I.</b>	<b>Equity and Liabilities</b>			
	<b>1. Shareholders' Funds</b>			
	(a) Share Capital	1	175,329,360	175,329,360
	(b) Reserves and Surplus	2	24,480,048	23,353,276
			<b>199,809,408</b>	<b>198,682,636</b>
	<b>4. Current liabilities</b>			
	(b) Trade payables	3	7,847,866	8,235,078
	(c) Other Current Liabilities	4	1,714,408	3,608,987
	(d) Short-term provisions	5	52,569	52,569
			<b>9,614,843</b>	<b>11,896,634</b>
	<b>TOTAL</b>		<b>209,424,251</b>	<b>210,579,270</b>
<b>II.</b>	<b>Assets</b>			
	<b>(1) Non-Current Assets</b>			
	(a) Non- current investments	6	208,709,137	209,826,584
			<b>208,709,137</b>	<b>209,826,584</b>
	<b>(2) Current assets</b>			
	(a) Trade Receivables	7	497	-
	(a) Cash and Cash Equivalents	8	391,281	295,419
	(b) Short-term Loans and Advances	9	323,090	457,267
	(d) Other Current Assets	10	246	-
			715,114	<b>752,686</b>
	<b>TOTAL</b>		<b>209,424,251</b>	<b>210,579,270</b>

**STRIDES PHARMA ASIA PTE. LTD**  
**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED March 31, 2023**

Amount in USD

	Particulars	Note No.	31-Mar-23	31-Mar-22
I	Other Income	11	2,389,421	43,294
II	<b>Total Revenue</b>		<b>2,389,421</b>	<b>43,294</b>
III	<b>Expenses</b>			
	Other Expenses	12	137,725	39,820
	Finance costs	13	2,770	3,561
	<b>Total</b>		<b>140,496</b>	<b>43,381</b>
IV	<b>Profit / (Loss) before exceptional items and taxes</b>		<b>2,248,926</b>	<b>(87)</b>
V	Exceptional expenses - Acquisition related costs		-	-
VI	<b>Profit / (Loss) before taxes</b>		<b>2,248,926</b>	<b>(87)</b>
VII	Tax Expense:			
	(1) Current tax		-	-
	(2) Deferred tax Liability / (Asset)		-	-
VIII	<b>Profit / (Loss) for the year after tax</b>		<b>2,248,926</b>	<b>(87)</b>

STRIDES PHARMA ASIA PTE. LTD

Notes forming part of the financial statements

Note

No.

1 Share capital

Amount in USD

Particulars	31-Mar-23	31-Mar-22
<b>Issued, subscribed and fully paid-up</b>		
Equity share capital	175,329,360	175,329,360
<b>Total</b>	<b>175,329,360</b>	<b>175,329,360</b>

STRIDES PHARMA ASIA PTE. LTD

Notes forming part of the financial statements

Note

No.

2 Reserves and surplus	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
<b>Surplus in Statement of Profit and Loss</b>		
Capital Reserve	(1,122,154)	-
Opening Balance	23,353,276	23,353,363
Add: Profit / (Loss) for the year	2,248,926	(87)
<b>Closing balance</b>	<b>24,480,048</b>	<b>23,353,276</b>
<b>Total</b>	<b>24,480,048</b>	<b>23,353,276</b>

3 Trade payables	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
Other than acceptances	7,847,866	8,235,078
<b>Total</b>	<b>7,847,866</b>	<b>8,235,078</b>

4 Other current liabilities	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
Payable to group entities	1,714,048	3,608,657
Other payables:		
- Statutory remittances	360	330
<b>Total</b>	<b>1,714,408</b>	<b>3,608,987</b>

5 Short-term provisions	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
<b>Provision - Others:</b>		
- Provision for tax (net of advance tax)	52,569	52,569
<b>Total</b>	<b>52,569</b>	<b>52,569</b>

6 Non - current investments	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
Strides Pharma Global Pte Limited	202,861,479	202,861,479
Stelis Biopharma (Malaysia) SDN BHD	1,376,186	1,376,186
Trinity Pharma (Pty) Limited	4,471,472	4,471,472
Arrow Pharma Pte Limited	-	1,117,447
<b>Total</b>	<b>208,709,137</b>	<b>209,826,584</b>

7 Trade receivables	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
Others		
- Unsecured considered good	497	-
<b>Total</b>	<b>497</b>	<b>-</b>

STRIDES PHARMA ASIA PTE. LTD

Notes forming part of the financial statements

8 Cash and cash equivalents	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
Bank balance	391,281	295,419
<b>Total</b>	<b>391,281</b>	<b>295,419</b>

9 Short-term loans and advances	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
<b>Unsecured, considered good</b>		
Loans and advances to Group entities	323,090	457,267
<b>Total</b>	<b>323,090</b>	<b>457,267</b>

10 Other Current Assets	Amount in USD	
Particulars	31-Mar-23	31-Mar-22
Prepaid expense	246	-
<b>Total</b>	<b>246</b>	<b>-</b>

**STRIDES PHARMA ASIA PTE. LTD**

**Notes forming part of the financial statements**

**Note**

**No.**

**11 Other Income**

**Amounts in USD**

<b>Particulars</b>	<b>31-Mar-23</b>	<b>31-Mar-22</b>
Profit/(Loss) on sale of investment	2,353,162	-
Other Income- Guarantee commission	8,688	6,401
Exchange fluctuation gain (net)	-	8,671
Interest Income	27,571	28,222
<b>Total</b>	<b>2,389,421</b>	<b>43,294</b>

**12 Other Expenses**

**Amounts in USD**

<b>Particulars</b>	<b>31-Mar-23</b>	<b>31-Mar-22</b>
Membership fees and subscription	654	635
Exchange fluctuation loss (net)	87,221	-
Professional fees	18,826	6,893
Rates and taxes	524	500
Payment to Auditors - For Statutory Audit	23,187	20,773
Director sitting fees	6,000	6,000
Support service expenses- Arcolab	1,313	1,317
Others	-	3,702
<b>Total</b>	<b>137,725</b>	<b>39,820</b>

**13 Finance Cost**

**Amounts in USD**

<b>Particulars</b>	<b>31-Mar-23</b>	<b>31-Mar-22</b>
Bank Charges & Commission	2,770	3,561
<b>Total</b>	<b>2,770</b>	<b>3,561</b>